BIIB
Biogen Inc.
225.40$
+2.9%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 32.6% | 34.4% | 38.2% | 33.3% | 30.2% | 30.8% | 28.0% | 32.9% | 39.9% | 25.6% | 26.6% | 30.5% | |
| 8.4% | 6.7% | 10.2% | 6.7% | 4.8% | 10.7% | 5.4% | 9.5% | 13.9% | 3.9% | 8.5% | 10.2% | |
| 12.9% | 17.6% | 21.4% | 15.6% | 14.0% | 16.4% | 10.6% | 15.9% | 19.9% | 3.9% | 8.5% | 13.0% | |
| 11.0% | 6.3% | 6.3% | 7.6% | 9.8% | 9.1% | 9.5% | 8.2% | 8.7% | 7.8% | 6.7% | 6.3% | |
| 5.6% | 4.6% | 4.4% | 3.8% | 3.7% | 3.0% | 4.3% | 5.7% | 5.5% | 9.4% | 8.8% | 7.4% | |
| 12.3% | 11.2% | 10.9% | 13.5% | 14.2% | 11.9% | 13.9% | 14.3% | 13.4% | – | – | – | |
| 12.3% | 13.7% | 16.0% | 19.6% | 22.6% | 21.1% | 23.4% | 24.1% | 23.4% | 23.2% | 23.1% | 22.0% | |
| 28.1% | 20.9% | 16.6% | 16.4% | 12.3% | 13.0% | 12.5% | 9.3% | 7.5% | 31.2% | 34.6% | 31.2% | |
| 24.5% | 51.9% | 47.0% | 46.7% | 48.5% | 51.0% | 56.6% | 54.1% | 45.5% | 44.9% | 40.4% | 38.0% | |
| 15.5% | 13.2% | 14.6% | 14.2% | 13.0% | 17.9% | 15.2% | 18.0% | 13.3% | 12.8% | 19.7% | 11.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | 5.5% | 0.7% | 4.2% | 0.8% | 0.6% | 6.2% | 0.3% | |
| 1.6% | 1.4% | 1.2% | 1.7% | 1.5% | 1.9% | 1.8% | 2.5% | 2.0% | 1.5% | 1.5% | 1.5% | |
| 4.1% | 33.4% | 28.5% | 25.1% | 23.5% | 16.4% | 30.2% | 26.3% | 25.6% | 25.3% | 16.2% | 21.4% | |
| 75.5% | 48.1% | 53.0% | 53.3% | 51.6% | 49.0% | 43.5% | 45.6% | 54.6% | 55.1% | 59.6% | 62.0% | |
| 64.8% | 62.6% | 65.9% | 66.8% | 64.3% | 60.4% | 56.8% | 58.3% | 67.1% | 65.7% | 68.7% | 69.8% | |
| 1.7% | 1.2% | 1.0% | 0.9% | 0.8% | 0.7% | 0.7% | 0.6% | 0.6% | 0.5% | 0.5% | 0.5% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.